The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

PHASE3RecruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Morning Sickness
Interventions
DRUG

Bonjesta

Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.

DRUG

Placebo

Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.

Trial Locations (10)

27043

RECRUITING

Unified Women's Clinical Research, Winston-Salem

29169

RECRUITING

Clinovacare Medical Research Center, West Columbia

32405

RECRUITING

Emerald Coast OB/GYN Clinical Research, Panama City

33016

RECRUITING

Vital Pharma Research, Hialeah

33165

RECRUITING

New Horizon Research Center, Miami

75149

RECRUITING

Axon Clinical Research, Mesquite

77573

RECRUITING

Maximos OBGYN, League City

77584

RECRUITING

Advances in Health, Pearland

83404

RECRUITING

Clinical Research Prime, Idaho Falls

91506

RECRUITING

Velvet Clinical Research, Burbank

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Premier Research

OTHER

lead

Duchesnay Inc.

INDUSTRY

NCT05289557 - The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents | Biotech Hunter | Biotech Hunter